Status In progress
Process STA
ID number 1209

Provisional Schedule

Committee meeting: 1 08 March 2018
Expected publication 15 August 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme
Others Department of Health
  NHS England
  NHS Bath and North East Somerset CCG
  NHS Fylde & Wyre CCG
  Welsh Government
Patient carer groups Action Bladder Cancer UK
  Black Health Agency
  Cancer 52
  Cancer Black Care
  Cancer Equality
  Fight Bladder Cancer
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Pelican Cancer Foundation
  Penny Brohns UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Gynaecological Cancer Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Urogynaecology
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
  Urology Foundation
  University College London Hospitals NHS Foundation Trust

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare/Actavis UK (carboplatin, gemcitabine)
  Eli Lilly (gemcitabine)
  Hospira UK (carboplatin, gemcitabine)
  Roche (atezolizumab – subject to ongoing NICE appraisal)
  Sun Pharmaceuticals UK (carboplatin, gemcitabine)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Prostate Diseases and Urologic Cancers Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Urothelial Cancers Research Group, Leeds Institute of Cancer & Pathology

Timeline

Key events during the development of the guidance:

Date Update
28 September 2017 In progress, In progress
26 September 2017 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance